FDA Approves IBTROZI Label Update with 49.7-Month Duration of Response in ROS1+ NSCLC
NUVB sits 93% above its 52-week low of $2.99.
Summary
The FDA approved a supplemental New Drug Application for IBTROZI, updating the label to include a median duration of response of 49.7 months in TKI-naïve ROS1+ NSCLC patients from the TRUST-I study. This is the longest median DOR reported for an FDA-approved ROS1 TKI and comes four months ahead of the PDUFA date. No changes to safety sections were required, reinforcing the drug's tolerability profile. The approval strengthens IBTROZI's competitive positioning in the ROS1+ NSCLC market and provides physicians with label-level evidence to support earlier use. The company's Q2 revenue beat and recent $250M convertible note offering provide a solid financial backdrop for this regulatory milestone.
At the time of this announcement, NUVB was trading at $5.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.99 to $9.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.